Abstract PS5-01-27: Outcomes by hormone receptor (HR) status in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with brain metastases (BM) treated with trastuzumab deruxtecan (T-DXd): a post-hoc subgroup analysis of DESTINY-Breast12
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: KU Leuven, LMU Klinikum, Ludwig-Maximilians-Universität München, Hospital Universitario 12 De Octubre, University of Liège, Centre Hospitalier Universitaire de Liège, University Medical Center Hamburg-Eppendorf, Tokai University, European Institute of Oncology, Medical University of Vienna, University Hospital of Basel, St. Vincent's University Hospital, University College Cork, Royal North Shore Hospital, University of Padua, IRCCS Ospedale San Raffaele, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, AstraZeneca (United Kingdom), AstraZeneca (United States), Dana-Farber Cancer Institute
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129333232
Cites:
Cited by:
Related to: